TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07166354: Phase 1/2 Randomized Study of Follicular Androgen Receptor Modulator AB-104 in Androgenetic Alopecia

Sponsor: Applied Biology, Inc. · Phase: PHASE1/PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 100 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$7,017,600

Rescue Site Savings

+$4,627,230

Unlock Full NCT07166354 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07166354 Rescue Dossier →